Biologics in children's autoimmune disorders: efficacy and safety. - Wikidata - wikimedia - TriplyDB

Biologics in children's autoimmune disorders: efficacy and safety.

Biologics in children's autoimmune disorders: efficacy and safety.

http://www.wikidata.org/entity/Q37765830

about

Immunization of children with secondary immunodeficiency Neutralizing anti-interleukin-1β antibodies modulate fetal blood-brain barrier function after ischemia.TNF-α Polymorphisms in Juvenile Idiopathic Arthritis: Which Potential Clinical Implications?A successful treatment of juvenile idiopathic arthritis with rituximab: A report of two cases.Role of adalimumab in the management of children and adolescents with juvenile idiopathic arthritis and other rheumatic conditions.Etanercept: efficacy and safety for approved indications.Making progress: preserving beta cells in type 1 diabetes.B cells participate in tolerance and autoimmunity through cytokine production.New age of biological therapies in paediatric rheumatology.Republished: new age of biological therapies in paediatric rheumatology.Juvenile idiopathic arthritis: management and therapeutic options.[Immunotherapy and infectious issues in multiple sclerosis. Self-injectable and oral drugs for immunotherapy].Immune response to influenza vaccination in children treated with methotrexate or/and tumor necrosis factor-alpha inhibitors.Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety.Guidelines for medical treatment of acute Kawasaki disease: report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version).

P2860

Q26801474-7467D142-F471-442E-B087-76BE45F01C20 Q27308341-9AC65F95-C8CC-4149-AE16-1DF3D59810DB Q36361083-63FA953A-0546-49CB-A649-2B73C6E69F97 Q37296422-DA06609A-E86F-4A45-9DA5-3BC87252E5BE Q37561994-78E0B220-DC72-4E54-9AF9-6CA6B61549BE Q37954714-35F04048-571E-4FB5-B7AA-E38801A735D8 Q37972677-0802B741-4D10-4560-8F33-26EEEB703468 Q38163603-F12BE81B-6C83-4DA8-8AC8-FBA2CC5C02EC Q38195363-BDC9A528-8B81-49F3-B0C5-5A4719C34718 Q38250593-FB51D5DD-B5CB-4CF4-BE28-2FE5B75E033F Q39243858-5D74CBC2-E08B-42AE-9398-81D6CAB2CE02 Q41102110-5162649F-BB6D-4E93-88AA-D03DE3C8FEE1 Q43762363-0E528E01-A8FE-40FE-A556-B41C98FF8BF0 Q51146578-96773269-C01D-4750-874A-9CC33D918399 Q54144614-A7B4ACFE-A579-46F8-9F6B-12E24D0DF9C2

P2860

Biologics in children's autoimmune disorders: efficacy and safety.

http://www.wikidata.org/entity/Q37765830

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 June 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Biologics in children's autoimmune disorders: efficacy and safety.

@en

Biologics in children's autoimmune disorders: efficacy and safety.

@nl

type

label

Biologics in children's autoimmune disorders: efficacy and safety.

@en

Biologics in children's autoimmune disorders: efficacy and safety.

@nl

prefLabel

Biologics in children's autoimmune disorders: efficacy and safety.

@en

Biologics in children's autoimmune disorders: efficacy and safety.

@nl

P1433

Q37765830-353B1A14-40D7-4BC8-9F95-1895D626F6A9

P1476

Q37765830-57CF033C-3D6D-46F0-8788-E5711A91AD26

P2093

Q37765830-17F4FB0F-2B29-4CD2-B242-711ACDD34F5E

Q37765830-BB47FC02-9110-4F5E-AE50-7150F4EAEADD

Q37765830-DCC3D5A1-7581-4093-BBC7-AEAF9CFEA99B

Q37765830-E90D3992-7924-4C67-B376-C9243668C179

P2860

Q37765830-0047378B-16D9-416D-AC0D-203099B3F128

Q37765830-011CC394-206D-4322-BC1A-A922BC9EC5DA

Q37765830-05650CCA-E5B8-4C67-BB64-36EB3B81E72F

Q37765830-0D825439-C251-4398-A25C-4F06470F789F

Q37765830-10F6C8D9-35FD-42DD-B955-C565A26D8BB0

Q37765830-12D7D329-930F-460C-88BD-3F75998D70BB

Q37765830-168CD9A6-69B1-4CEF-BCE5-0DDA4B3D47AB

Q37765830-1C525DAD-C832-4EEE-8605-56C4884FE1F0

Q37765830-1CE2E9C2-9FD5-47E4-9E8E-42ACB2F4F591

Q37765830-207F726E-7F71-46CD-BF43-49CC4F56F37B

P2888

Q37765830-7B5FF4D2-7DEA-40F4-869A-B6B216B4BE33

P304

Q37765830-68F8704F-99A4-4908-83B1-6A142A93B09C

P31

Q37765830-3B4BB139-D532-4190-9269-561F6AA14665

P356

Q37765830-C91308AC-B9CE-4503-AE8B-CAC066C85853

P433

Q37765830-CA720990-D3B8-4EB6-B80E-31609277AB11

P478

Q37765830-32988DA7-E626-4E03-8405-8EBD53A4256E

P577

Q37765830-5E7EFB18-249D-4425-8994-0B6ABBB010FA

P698

Q37765830-E0C50EF3-5677-42F2-B2A3-857D84892A55

P356

S00431-010-1238-Z

P1433

European Journal of Pediatrics

P1476

Biologics in children's autoimmune disorders: efficacy and safety.

@en

P2093

Francesco Chiarelli

http://www.w3.org/2001/XMLSchema#string

Luciana Breda

http://www.w3.org/2001/XMLSchema#string

Marianna Del Torto

http://www.w3.org/2001/XMLSchema#string

Sara De Sanctis

http://www.w3.org/2001/XMLSchema#string

P2860

Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome

Infliximab for induction and maintenance therapy for ulcerative colitis

Replacing the complementarity-determining regions in a human antibody with those from a mouse

Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease.

Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.

Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura

Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias.

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.

P2888

s00431-010-1238-z

P304

157-167

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00431-010-1238-Z

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

170

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20556424

http://www.w3.org/2001/XMLSchema#string